SCHEMBL25323015

SCHEMBL25323015

Nc1cnc(Br)c2nn(C3CCCCO3)cc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.34
ALDH1A1 P00352 4/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
TP53 P04637 1/20 0.34
CYP2C9 P11712 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
APEX1 P27695 1/20 0.34
PI4KA P42356 1/20 0.34
BLM P54132 1/20 0.34
ADCY1 Q08828 1/20 0.34
PI4K2B Q8TCG2 1/20 0.34
PI4K2A Q9BTU6 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
RET P07949 4/20 0.33
POLB P06746 2/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322988 0.81 RET (0.42) CYP2C19ALDH1A1KMT2AMEN1TP53
SCHEMBL25320869 0.80 ALDH1A1 (0.41) CYP2C19ALDH1A1KMT2AMEN1TP53
SCHEMBL457479 0.73 CYP2C19 (0.33) CYP2C19ALDH1A1KMT2ARETPOLB
SCHEMBL28801167 0.72 RET (0.35) CYP2C19ALDH1A1KMT2AMEN1TP53
SCHEMBL24274286 0.71 GAA (0.30) CYP2C19GAAYTHDC1
SCHEMBL31178702 0.71 ALDH1A1 (0.33) CYP2C19ALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL29474165 0.71
SCHEMBL114987 0.70 ALDH1A1 (0.33) CYP2C19ALDH1A1KMT2AMEN1TP53
SCHEMBL31014874 0.70 ALDH1A1 (0.35) CYP2C19ALDH1A1KMT2ARETPOLB
SCHEMBL15263438 0.70 CYP4F2 (0.34) CYP2C19ALDH1A1KMT2APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN CYP2C19 12/4885ALDH1A1 79/4885KMT2A 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.